BlackRock Investment Management
LCTX icon

BlackRock Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

BlackRock Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1M Buy
318,291
+3,297
+1% +$10.1K ﹤0.01% 2692
2016
Q3 		$1.07M Buy
314,994
+48,758
+18% +$135K ﹤0.01% 2619
2016
Q2 		$608K Buy
266,236
+49,312
+23% +$121K ﹤0.01% 2951
2016
Q1 		$545K Sell
216,924
-12,117
-5% -$27K ﹤0.01% 2863
2015
Q4 		$758K Buy
229,041
+3,427
+2% +$10.2K ﹤0.01% 2782
2015
Q3 		$546K Sell
225,614
-7,509
-3% -$19.4K ﹤0.01% 2994
2015
Q2 		$683K Buy
233,123
+44,420
+24% +$172K ﹤0.01% 3010
2015
Q1 		$757K Buy
188,703
+1,214
+0.6% +$4.2K ﹤0.01% 2714
2014
Q4 		$564K Hold
187,489
– – ﹤0.01% 2945
2014
Q3 		$475K Buy
187,489
+4,616
+3% +$11.1K ﹤0.01% 3000
2014
Q2 		$450K Buy
182,873
+55,895
+44% +$126K ﹤0.01% 3093
2014
Q1 		$337K Sell
126,978
-501
-0.4% -$1.48K ﹤0.01% 3120
2013
Q4 		$370K Sell
127,479
-1,288
-1% -$3.89K ﹤0.01% 3096
2013
Q3 		$395K Buy
128,767
+10,076
+8% +$31.9K ﹤0.01% 3028
2013
Q2 		$379K Buy
+118,691
New +$380K ﹤0.01% 2995

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
Destination Wealth Management
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock Investment Management's LCTX Position: Q4 2016 in Review

BlackRock Investment Management increased its Lineage Cell Therapeutics (LCTX) stake by 1% in Q4 2016, buying an estimated $10.1K and bringing the position to 318,291 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

BlackRock Investment Management first reported a position in LCTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.07M in Q3 2016. 92 funds tracked by Wall St. Rank hold LCTX as of Q4 2016.

  • BlackRock Investment Management held 318,291 shares of Lineage Cell Therapeutics worth $1M as of Q4 2016.
  • BlackRock Investment Management bought 3,297 Lineage Cell Therapeutics shares in Q4 2016, an estimated $10.1K.
  • Lineage Cell Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2692 holding.
  • BlackRock Investment Management first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Lineage Cell Therapeutics position peaked at $1.07M in Q3 2016.
  • 92 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.